Compare IGA & ANIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IGA | ANIX |
|---|---|---|
| Founded | 2005 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 151.6M | 135.3M |
| IPO Year | N/A | 1987 |
| Metric | IGA | ANIX |
|---|---|---|
| Price | $9.78 | $3.27 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 42.3K | ★ 353.5K |
| Earning Date | 01-01-0001 | 01-09-2026 |
| Dividend Yield | ★ 8.93% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.77 | $2.07 |
| 52 Week High | $8.88 | $5.46 |
| Indicator | IGA | ANIX |
|---|---|---|
| Relative Strength Index (RSI) | 60.38 | 33.85 |
| Support Level | $9.72 | $4.20 |
| Resistance Level | $9.79 | $5.46 |
| Average True Range (ATR) | 0.08 | 0.43 |
| MACD | 0.02 | -0.13 |
| Stochastic Oscillator | 78.18 | 2.77 |
Voya Global Advantage and Premium Opportunity Fund is a United States-based diversified, closed-end management investment company. The fund has two investment objectives. Its primary objective is to provide a high level of income, while the secondary objective is to seek capital appreciation. To achieve these objectives, the fund invests at least 80% of its managed assets in a portfolio of common stocks from various countries around the world, including the United States. Additionally, it uses an integrated derivatives strategies.
Anixa Biosciences Inc a cancer-focused biotechnology company, develops vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.